Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
Eur J Endocrinol ; 2024 Sep 29.
Artigo em Inglês | MEDLINE | ID: mdl-39343731

RESUMO

CONTEXT: Patients with primary aldosteronism (PA) have higher cardiac comorbidities including more pronounced left ventricular hypertrophy than patients with essential hypertension. OBJECTIVE: Autonomous cortisol co-secretion (ACS) is a common subtype in PA associated with a worse metabolic profile. HYPOTHESIS: ACS may affect myocardial parameters and result in a worse cardiac outcome compared to patients with PA and without ACS. METHODS: 367 patients with PA undergoing 1mg dexamethasone suppression test (DST) and echocardiography at baseline from two centers of the German Conn´s Registry were included. Follow-up for up to 3.8yrs was available in 192 patients. RESULTS: Patients with PA and ACS had higher NTpro-BNP levels at baseline compared to patients with PA without ACS (114vs75.6pg/ml,p=0.02), but showed no difference in echocardiography values. NTpro-BNP levels showed a significant positive correlation (r=0.141,p=0.011) with cortisol levels after DST at baseline. In response to therapy of PA, NTpro-BNP levels decreased, but remained significantly higher in patients with ACS compared to patients without ACS. At follow-up, left ventricle end diastolic dimension (LVEDD) decreased significantly only in patients without ACS. Left atrial diameter (LAD) decreased significantly in patients without ACS and in female patients with ACS but not in male patients. Left ventricular mass index (LVMI) significantly improved in female patients without ACS but remained unchanged in female patients with ACS as well as in male patients at follow-up. CONCLUSION: In patients with PA, concomitant ACS is associated with a worse cardiac profile and only partial recovery even years after initiation of targeted PA therapy.

2.
J Nucl Med ; 65(10): 1640-1644, 2024 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-39237344

RESUMO

C-X-C motif chemokine receptor 4 (CXCR4)-directed imaging has gained clinical interest in aiding clinical diagnostics in primary aldosteronism (PA). We retrospectively evaluated the feasibility of CXCR4-directed scintigraphy using the novel CXCR-4 ligand [99mTc]Tc-pentixatec in patients with PA. Methods: Six patients (mean age ± SD, 49 ± 15 y) underwent CXCR4-directed scintigraphy (including planar imaging and SPECT/CT) 30, 120, and 240 min after injection of 435 ± 50 MBq of [99mTc]Tc-pentixatec. Adrenal CXCR4 expression was analyzed by calculating lesion-to-contralateral ratios (LCRs). Imaging results were correlated to clinical information. Histopathology and clinical follow-up served as the standard of reference. Results: Three subjects showed lateralization of adrenal tracer accumulation, with a mean maximum lesion-to-contralateral ratio of 1.65 (range, 1.52-1.70), which correlated with morphologic findings on CT. One individual underwent adrenalectomy and presented with complete biochemical and clinical remission at follow-up. Histopathologic workup confirmed unilateral aldosterone-producing adenoma. Conclusion: [99mTc]Tc-pentixatec scintigraphy with SPECT in patients with PA is feasible and might offer a valuable alternative to CXCR4-directed imaging with [68Ga]Ga-pentixafor PET.


Assuntos
Hiperaldosteronismo , Compostos de Organotecnécio , Receptores CXCR4 , Humanos , Pessoa de Meia-Idade , Hiperaldosteronismo/diagnóstico por imagem , Masculino , Feminino , Receptores CXCR4/metabolismo , Adulto , Estudos Retrospectivos , Estudo de Prova de Conceito , Idoso , Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único , Compostos Radiofarmacêuticos , Glândulas Suprarrenais/diagnóstico por imagem
3.
Eur J Endocrinol ; 190(4): K47-K52, 2024 Mar 30.
Artigo em Inglês | MEDLINE | ID: mdl-38557596

RESUMO

Accumulating evidence links osteoporosis and dietary salt consumption. Primary aldosteronism (PA) is a model disease with increased dietary salt intake and constitutes an independent risk factor for osteoporosis. We, thus, assessed whether a short-term moderate reduction in salt intake in PA results in detectable osteoanabolic effects. Forty-one patients with PA on stable mineralocorticoid receptor antagonist therapy were subjected to a 12-week salt restriction. Serum and urinary electrolytes, markers of bone turnover, and a 15 steroids plasma profile were registered. After 12 weeks, urinary calcium and phosphate decreased, while plasma testosterone, serum phosphate, and bone alkaline phosphatase (BAP) all increased significantly. Longitudinal changes in BAP were independently correlated with changes in serum phosphate, parathyroid hormone, and urinary calcium in multivariate analysis. Salt restriction in PA limits urinary calcium and phosphate losses and may confer favorable osteoanabolic effects. Our findings suggest that salt restriction should be considered in patients with PA to improve bone health.


Assuntos
Hiperaldosteronismo , Osteoporose , Humanos , Cloreto de Sódio na Dieta , Cálcio , Fosfatos , Hormônio Paratireóideo
4.
Hypertension ; 81(4): 936-945, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38318706

RESUMO

BACKGROUND: Primary aldosteronism (PA) is frequently caused by a unilateral aldosterone-producing adenoma with a PA-driver mutation. Unilateral adrenalectomy has a high probability of short-term biochemical remission, but long-term postsurgical outcomes are relatively undefined. Our objective was to investigate the incidence of long-term recurrence of PA in individuals with postsurgical short-term biochemical remission. METHODS: Adrenalectomized patients for unilateral PA were included from a single referral center. Histopathology and outcomes were assessed according to international histopathology of unilateral primary aldosteronism and PASO (Primary Aldosteronism Surgical Outcome) consensuses. Genotyping was performed using CYP11B2 (aldosterone synthase)-guided sequencing. RESULTS: Classical adrenal histopathology, exemplified by a solitary aldosterone-producing adenoma, was observed in 78% of 90 adrenals, compared with 22% with nonclassical histopathology. The classical group displayed higher aldosterone-to-renin ratios (P=0.013) and lower contralateral ratios (P=0.008). Outcome assessments at both short (12 months [7; 12]) and long (89 months [48; 124]) terms were available for 57 patients. At short-term assessment, 53 (93%) displayed complete biochemical success (43 classical and 10 nonclassical), but long-term assessment demonstrated biochemical PA recurrence in 12 (23%) with an overrepresentation of the nonclassical histopathology (6 [60%] of 10 nonclassical histopathology versus 6 [14%] of 43 classical histopathology; P=0.005). PA-driver mutations were identified in 97% of 64 aldosterone-producing adenomas; there was no association of the aldosterone-producing adenoma genotype with PA recurrence. CONCLUSIONS: A substantial proportion of individuals display postsurgical biochemical recurrence of PA, which is related to the histopathology of the resected adrenal gland. These findings emphasize the role of histopathology and the requirement for continued outcome assessment in the management of surgically treated patients for PA.


Assuntos
Adenoma , Adenoma Adrenocortical , Hiperaldosteronismo , Humanos , Adrenalectomia , Aldosterona , Recidiva Local de Neoplasia/cirurgia , Hiperaldosteronismo/diagnóstico , Hiperaldosteronismo/genética , Hiperaldosteronismo/cirurgia , Adenoma Adrenocortical/genética , Adenoma Adrenocortical/cirurgia , Adenoma/cirurgia , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...